Table 2.
Delays in Cancer Treatment among Cancer Patients
| Limited HL (N = 210) |
Adequate HL (N = 1,015) |
All Participants (N = 1225) |
P-value | |
|---|---|---|---|---|
| Cancer Type, n (%)a | ||||
| Bladder Cancer | 4 (1.9%) | 14 (1.3%) | 18 (1.5%) | 0.702 |
| Bone Cancer | 3 (1.4%) | 14 (1.3%) | 17 (1.4%) | 0.909 |
| Breast Cancer | 46 (21.9%) | 422 (41.6%) | 468 (38.2%) | < 0.001 |
| Cervical Cancer | 3 (1.4%) | 11 (1.1%) | 14 (1.1%) | 0.794 |
| Colon Cancer | 14 (6.7%) | 38 (3.7%) | 52 (4.2%) | 0.123 |
| Endometrial Cancer | 6 (2.8%) | 57 (5.6%) | 63 (5.1%) | 0.056 |
| Head & Neck Cancer | 14 (6.7%) | 30 (3.0%) | 44 (3.6%) | 0.024 |
| Leukemia/ Blood Cancer | 16 (7.6%) | 91 (9.0%) | 107 (8.7%) | 0.300 |
| Liver Cancer | 8 (3.8%) | 18 (1.8%) | 26 (2.1%) | 0.112 |
| Lung Cancer | 30 (14.2%) | 80 (7.9%) | 110 (9.0%) | 0.017 |
| Hodgkin’s Lymphoma | 5 (2.3%) | 8 (0.8%) | 13 (1.1%) | 0.067 |
| Non-Hodgkin’s Lymphoma | 20 (9.5%) | 75 (7.4%) | 95 (7.8%) | 0.548 |
| Melanoma | 25 (11.9%) | 115 (11.3%) | 140 (11.4%) | 0.783 |
| Oral Cancer | 2 (1.0%) | 6 (0.6%) | 8 (0.7%) | 0.648 |
| Ovarian Cancer | 11 (5.2%) | 50 (4.9%) | 61 (4.9%) | 0.888 |
| Pancreatic Cancer | 2 (1.0%) | 11 (1.1%) | 13 (1.1%) | 0.757 |
| Pharyngeal (throat) Cancer | 0 (0%) | 10 (1.0%) | 10 (0.8%) | 0.128 |
| Prostate Cancer | 17 (8.1%) | 55 (5.4%) | 72 (5.9%) | 0.276 |
| Rectal Cancer | 7 (3.3%) | 11 (1.1%) | 18 (1.5%) | 0.027 |
| Renal (kidney) Cancer | 3 (1.4%) | 30 (3.0%) | 33 (2.7%) | 0.152 |
| Non-melanoma Skin Cancer | 21 (10.0%) | 106 (10.4%) | 127 (10.4%) | 0.510 |
| Stomach Cancer | 2 (1.0%) | 10 (1.0%) | 12 (1.0%) | 0.855 |
| Other Cancer | 28 (13.3%) | 89 (8.7%) | 117 (9.6%) | 0.133 |
| Number of cancer patients scheduled for any cancer-related medical care that had to be cancelled or rescheduled during the COVID-19 restrictions, n (%) | 37 (17.6%) | 206 (20.3%) | 243 (19.8%) | 0.171 |
| What did you have to cancel or reschedule?b | ||||
| Routine appointmentc | 30 (14.2%) | 167 (16.4%) | 197 (16.1%) | 0.309 |
| Screening test (i.e. mammogram, pap smear, colonoscopy) | 14 (6.7%) | 72 (7.1%) | 86 (7.0%) | 0.424 |
| Blood test | 9 (4.3%) | 65 (6.4%) | 74 (6.1%) | 0.370 |
| Surgery | 6 (2.8%) | 19 (1.9%) | 25 (2.0%) | 0.236 |
| Chemotherapy | 4 (1.9%) | 10 (1.0%) | 14 (1.1%) | 0.134 |
| Radiation therapy | 1 (0.4%) | 9 (0.9%) | 10 (0.8%) | 0.634 |
| Physical or Occupational therapy | 3 (1.4%) | 9 (0.9%) | 12 (1.0%) | 0.369 |
a A participant may have had more than one cancer diagnosis
b A participant with a prior cancer diagnosis may have had more than one cancer related treatment cancelled or rescheduled
c Routine appointment is defined as a standard follow-up visit for interim surveillance (not problem-focused or acute in nature)
Percentages are calculated among the health literacy group to be able to draw comparisons between health literacy group